Lanean...
Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date
Recombinant activated factor VII (rFVIIa) is a bypassing agent widely used both in the treatment and prevention of hemorrhagic complications due to hemophilia with inhibitor. In such cases, antihemophilic factors cannot be used. The normal physiology of factor VII/ factor VIIa (FVII/FVIIa) in the he...
Gorde:
| Argitaratua izan da: | Ther Adv Hematol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5703115/ https://ncbi.nlm.nih.gov/pubmed/29204261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717737701 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|